Lung Cancer Case Study

Similar documents
Slide 1. Slide 2. Slide 3. Investigation and management of lung cancer Robert Rintoul. Epidemiology. Risk factors/aetiology

Lung Cancer - Suspected

North of Scotland Cancer Network Clinical Management Guideline for Non Small Cell Lung Cancer

NICE Quality Standards and COF

Clinical Management Guideline for Small Cell Lung Cancer

For personal use only. Not to be reproduced without permission of the editor

Adam J. Hansen, MD UHC Thoracic Surgery

Tumor Board Discussions: Case 1

Lung cancer. The diagnosis and treatment of lung cancer. Issued: April NICE clinical guideline 121. guidance.nice.org.

GCE AS/A level 1661/01-A APPLIED SCIENCE UNIT 1

Bronchogenic Carcinoma

THORACIK RICK. Lungs. Outline and objectives Richard A. Malthaner MD MSc FRCSC FACS

Lung Cancer Clinical Guidelines: Surgery

Larry Tan, MD Thoracic Surgery, HSC. Community Cancer Care Educational Conference October 27, 2017

LUNG CANCER. Agnieszka Słowik, MD. Department of Oncology, University Hospital in Cracow Jagiellonian University

Lung Cancer-a primer. Sai Yendamuri, MD Professor and Chair, Dept of Thoracic Surgery,RPCI,Buffalo

Lung Cancer in Older Adults.. 2 Cases

Resources for health professionals (3) Risk Factors (5) Initial investigations (8) Red Flag (9) Diagnosis and staging (12)

LCA Lung Clinical Forum. 21 st October 2014

Lung Cancer Very common Very lethal Median age of diagnosis i approximately 70 years, but affects all ages In the United States, the highest incidence

Cancer of Unknown Primary (CUP) Protocol

Erlotinib Non-Small Cell Lung Cancer

Early Detection of Lung Cancer

3/30/2009 Lung Cancer Deaths 2008 Lung Cancer Deaths Lung Cancer Deaths--Males Males 5

Lung Cancer Incidence 2008 Lung Cancer Deaths-Males 2008 Incidence Total U.S.(all types): 1,437,180 Lung Cancer Deaths-Females Lung cancer 215,000(15%

Thoracic Surgery; An Overview

Molly Boyd, MD Glenn Mills, MD Syed Jafri, MD 1/1/2010

Lung cancer forms in tissues of the lung, usually in the cells lining air passages.

Respiratory Interactive Session. Elaine Borg

Bronchiectasis in Adults - Suspected

The Management of Lung Cancer. Pathway of Care. Kent & Medway Cancer Collaborative

Charles Mulligan, MD, FACS, FCCP 26 March 2015

Surgical management of lung cancer

Lung Cancer. This reference summary will help you better understand lung cancer and the treatment options that are available.

Guide to Understanding Lung Cancer

Investigating Symptoms of Lung Cancer An evidence based Guide for general practitioners

Better Outcomes for Lung Cancer in Family Practice. AProf Jeff Garrett Respiratory Physician

National Optimal Lung Cancer Pathway

An Update: Lung Cancer

Lung cancer: the diagnosis and treatment of lung cancer (partial update of NICE clinical guideline 24)

NICE guideline Published: 10 February 2016 nice.org.uk/guidance/ng36

Lung cancer is a disease in which malignant (cancer) cells form in the tissues of the lung.

NICE guideline Published: 10 February 2016 nice.org.uk/guidance/ng36

The diagnosis and treatment of lung cancer

Lung Cancer: Diagnosis, Staging and Treatment

Dr Greg Frazer. Respiratory Physician Christchurch Hospital Christchurch. 15:10-15:35 Primary and Secondary Healthcare Interface Supported by:

Clinical guideline Published: 21 April 2011 nice.org.uk/guidance/cg121

Lung Cancer Treatment

Clinical Advice to Cancer Alliances for the Commissioning of the whole Lung Cancer Pathway

Audit Report. Lung Cancer Quality Performance Indicators. Patients diagnosed January December Published: November 2017

Case Scenario 1. The patient agreed to a CT guided biopsy of the left upper lobe mass. This was performed and confirmed non-small cell carcinoma.

Mediastinal Staging. Samer Kanaan, M.D.

Audit Report. Lung Cancer Quality Performance Indicators. Patients diagnosed April 2014 March Published: May 2016

Breathlessness in advanced disease. February 2017

Lung Cancer. Definition of lung cancer Malignancy arising from lung tissue

Bladder Cancer Guidelines

North of Scotland Cancer Network Clinical Management Guideline for Carcinoma of the Uterine Cervix

Lung Cancer Update. HARMESH R NAIK, MD. February 28, 2001

Endobronchial Ultrasound in the Diagnosis & Staging of Lung Cancer

Cancer of the upper aerodigestive tract: assessment and management in people aged 16 and over

THORACIC MALIGNANCIES

Common things are common, but not always the answer

Definition. Epidemiology. Lung Cancer is a disease which cancer (malignant tumors) cells grow in the lungs. LUNG CANCER Debra Mercer BSN, RN, RRT

MANAGING LUNG CANCER GP CME South Roland Meyer Respiratory Physician, Southern DHB

LCA Lung Cancer Clinical Guidelines. December 2013 (updated March 2016)

Lung cancer LUNG CANCER. Box 1 Clinical signs

CELL-MEDIATED IMMUNITY

North of Scotland Cancer Network Clinical Management Guideline for Mesothelioma

A CRP B FBC C LFT D blood culture E uric acid

Days. Visits, Tests and Procedures

Patient information from BMJ

ANZUP SURVEILLANCE RECOMMENDATIONS FOR METASTATIC TESTICULAR CANCER POST-CHEMOTHERAPY

Understanding surgery

GROUP 1: Peripheral tumour with normal hilar and mediastinum on staging CT with no disant metastases. Including: Excluding:

Clinical Radiological Pathological Conference

Endobronchial Ultrasound in the Diagnosis & Staging of Lung Cancer

Understanding Pleural Mesothelioma

Tongue cancer. Patient information

LONDON CANCER NEW DRUGS GROUP RAPID REVIEW. Erlotinib for the third or fourth-line treatment of NSCLC January 2012

Lung Cancer. Current Therapy JEREMIAH MARTIN MBBCh FRCSI MSCRD

BRONCHOGENIC CARCINOMA CHALLENGES IN EVALUATION

Early and locally advanced non-small-cell lung cancer (NSCLC)

GUIDELINES FOR CANCER IMAGING Lung Cancer

PATHWAY FOR INVESTIGATION OF ADULTS PRESENTING WITH ASCITES. U/S Abdo/pelvis shows ascites without obvious evidence of 1 liver disease

WELLNESS INITIATIVE NOW

EVIDENCE BASED MANAGEMENT OF STAGE III NSCLC MILIND BALDI

Video-Mediastinoscopy Thoracoscopy (VATS)

North of England Cancer Network. NECN Lung Cancer Clinical Guidelines

Sleeve lobectomy for lung adenocarcinoma treated with neoadjuvant afatinib

Lung Cancer in Women: A Different Disease? James J. Stark, MD, FACP

Scottish Audit of Head and Neck Cancers. A Prospective Audit

SCLERODERMA LUNG DISEASE: WHAT THE PATIENT SHOULD KNOW

LUNG CANCER: LDCT DISCLOSURES NONE. Erika Swanson, MD Radiation Oncologist Ascension Columbia-St. Mary s February 1, /9/2018

SIGN 137 Management of lung cancer. A national clinical guideline February Evidence

Lung Cancer. you can face it if you know it better

and Strength of Recommendations

Chirurgie beim oligo-metastatischen NSCLC

Interventional Pulmonology

Treatment of oligometastatic NSCLC

Respiratory Medicine

Transcription:

Lung Cancer Case Study Presented by s GP Education Programme

2 Part One Initial presentation 60 year old lady, presents with a 6 week history of right sided chest pain. The pain is like a dull ache, but comes and goes. It is eased with occasional paracetamol use. It has not changed over the last few weeks; neither worsening or improving Respiratory examination is unremarkable and there is no chest wall tenderness.

3 Q1. What other information would you like to elicit? Smoking history Any symptoms of infection Haemoptysis Change in voice Family History Cough Weight loss Asbestos exposure

4 Q2. What are the differential diagnoses?

5 Q3. What investigations could you perform at this stage if any? None CXR if not done recently Spirometry FBC- anaemia, thrombocytosis

6 She is an ex-smoker, having smoked from the age of 16 to 52; she smoked 20 cigarettes a day. She has a family history of lung cancer, with her father dying from the disease at the age of 64. She has lost around five pounds in the last three months, but she has been trying to lose weight. She has a CXR which is reported as normal.

7 Q4. From her history does she have any risk factors the development of lung cancer? Duration of smoking history Stopped smoking less than 10 years ago Family history of lung cancer

8 Q5. From her presentation, does she have any symptoms which suggest a diagnosis of lung cancer Chest pain Weight loss

9 Part Two She attends your surgery after being seen in a TWR clinic by a respiratory physician She has undergone a CT scan of the lower neck, chest and abdomen. The respiratory physician has explained that she probably has lung cancer but requires further investigations with a PET, PFTs, CT brain and perhaps an EBUS. She has evidence of obstructive airway disease on spirometry and has been commenced on inhalers. She is told that surgery may be an option.

10 Q1. She is concerned that more tests are being done and the delay in just getting rid of it. What are the further investigations and why are they important? PET- Positron Emission Tomography- nuclear imaging performed to fully stage lung cancer. Can be pick up area of metastatic disease not detected by conventional CT, especially bone metastases EBUS- Endobronchial Ultrasound- used to investigate mediastinal nodes and obtain tissue by transbronchial nodal aspiration to ascertain the type of lung cancer CT brain- to enable full staging prior to undergoing treatment with curative intent PFTs- Pulmonary function tests- to evaluate lung function to enable treatment planning.

11 Q2. She wishes to stop the inhalers she has been prescribed. Why should she continue with these? It is important to maximise lung function prior to any definitive treatment. Pulmonary function tests will be undertaken to help ascertain whether a patient can withstand a surgical resection or treatment with radical radiotherapy

12 Q3. Where does lung cancer commonly metastasise to? Liver Bone Brain Adrenals Other parts of the lung Lymph-nodes

13 Q4. She is fearful of undergoing surgery. Are there any other options, which may still offer a cure? Depends upon tumour size, site and the involvement of lymph nodes Radical chemoradiotherapy Sterotatic ablative radiotherapy (SABR)

14 Q5. If she elects to undergo surgery what are the possible options and will she need any other treatment afterwards? Type of surgical resection will depend on the position of the tumour, whether there is lymph node involvement, lung function and co-morbidities Can include Lobectomy and lymph node dissection Pneumonectomy and lymph node dissection Wedge resection May need chemotherapy after surgery depending on tumour size and lymph node involvement Occasionally radiotherapy is needed if there are positive resection margins

15 Part three Management in primary care She has undergone a lobectomy and adjuvant chemotherapy at 18 months ago. She was diagnosed with a 3.3 cm adenocarcinoma of the lung, with involvement of a hilar lymph node. She was last seen three months ago by a respiratory physician when a CXR was unchanged. She is being seen by her oncologist every six months and has an appointment in two months time. She is now fatigued and complaining of weight loss.

16 Q1. What investigations are appropriate at this stage? History to ascertain if her symptoms could be due to the development of metastatic disease. Physical examination to look for evidence of metastatic disease (pleural effusion, hepatomegaly, cervical lymph nodes). Urgent referral back to oncologist for imaging chest and abdomen?fbc (anaemia), LFT (abnormal ALT or ALP)

17 Q2. What is her 5 year survival following surgery? Final pathological stage was T2 N1 M0, stage 2B 5-year survival is around 25-36% Most relapses occur within the first 18 months Stage 1A 1B 2A 2B 3A 3B 5-year survival ~ 58-73% ~ 43-58% ~ 36-46% ~ 25-36% ~ 19-24% ~ 7-9% 4 ~ 4-10%

18 She has developed liver and adrenal metastases and has been told that she now has incurable disease. Treatment is aimed at improving her symptoms and may lengthen her survival. She has been asked to undergo another biopsy to allow molecular testing as if she has a mutation she may be able to have a tablet rather than chemotherapy

19 Q3. What are the treatment options of advanced lung cancer Palliative chemotherapy, in adenocarcinoma this would be with pemetrexed and a platinum agent given every three weeks, possibly followed by maintenance chemotherapy If the tumour contains an sensitising mutation in the epidermal growth factor receptor (EGFR), treatment with an EGFR targeted tyrosine kinase inhibitor Palliative radiotherapy for symptom control Bisphosphonate given intravenously to prevent skeletal events in patients with bone metastases

20 Q4. She elects for treatment with a oral tyrosine kinase inhibitor. What are the common side-effects? Diarrhoea Acne like rash affecting face, chest, back and scalp Dry skin Dry eyes Fatigue Hair growth, including eyelashes and facial hair Mouth ulcers Brittle nails Pneumonitis Interaction with clarithromycin, erythromycin and fluconazole

21 Risk factors for developing lung cancer Smoking history COPD Asbestos exposure Family History >40 years old Previous history of cancer History of pneumonia Autoimmune conditions e.g. Rheumatoid arthritis

22 Symptoms of lung cancer? Cough Haemoptysis Dyspnoea Weight loss Chest pain Shoulder pain Fatigue Hoarse voice Finger clubbing Cervical/supraclavicular lymph nodes

23 When to refer? Persistent symptoms last more than 3 weeks CXR suggestive of lung cancer- CXR can be normal Signs of superior vena cava obstruction Stridor Symptoms suggestive of metastatic diseaseunremitting pain, weight loss, shortness of breath.

24 Investigations? Primary Care CXR FBC Secondary care CT chest and abdomen PET CT brain if considering treatment with curative intent Pulmonary function test Bone scan if PET not done Mediastinocopy or EBUS for nodal staging

25 Treatment options? Curative Surgery Radical radiotherapy +/- chemotherapy Stereotatic radiotherapy Palliative Chemotherapy Targeted therapies Radiotherapy Bisphosphonates Bronchial stents Pleurodesis

How can you help? Think about a possible diagnosis of cancer Encourage stopping smoking Diagnosing COPD and optimising pulmonary function whilst your patient is undergoing investigation Optimising pulmonary function after surgical resection